Andrew Maes, DO
Urology · Berlin, WINPI 1841496619
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,812 of the $7,881 with a category attached, or 61.1%. 28 manufacturers reported payments, led by Medtronic at 28.6% of the total. Reporting peaked in 2019 at $2,914 and has fallen 96.1% since, to $114 in 2025. Among urology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Astellas Pharma US Inc$1K
- Teleflex LLC$908
- Pfizer$623
- AbbVie$404
- Johnson & Johnson$376
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$2,00025%
- Food & beverage$4,81261%
- Education$1,03513%
- Gifts$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $2,258 |
| Astellas Pharma US Inc | 40 | $1,232 |
| Teleflex LLC | 16 | $908 |
| Pfizer | 45 | $623 |
| AbbVie(2 entities) | 28 | $404 |
| Johnson & Johnson | 15 | $376 |
| Neotract Inc. | 13 | $309 |
| Axonics, Inc. | 8 | $240 |
| Endo Pharmaceuticals Inc. | 10 | $205 |
| Boston Scientific | 7 | $175 |
| Merck | 11 | $175 |
| Sumitomo Pharma America, Inc. | 9 | $161 |
| Coloplast | 6 | $157 |
| Bayer | 6 | $106 |
| Urogen Pharma, Inc. | 4 | $79 |
| Tolmar, Inc. | 4 | $77 |
| Urovant Sciences Inc | 4 | $63 |
| Intuitive Surgical | 3 | $58 |
| Novartis | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $54 |
| Amgen | 2 | $39 |
| AstraZeneca | 2 | $29 |
| Myovant Sciences Inc. | 2 | $26 |
| Bluewind Medical | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,000
- UroLift System$300
- UroLift$261
- Bulkamid$149
- TITAN$101
How this compares
$7,881 in reported general payments places this provider in the 90th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 66 | $854,038 |
| MyrbetriqMirabegron | 260 | $172,964 |
| GemtesaVibegron | 80 | $64,495 |
| Abiraterone Acetate | 13 | $63,739 |
| XgevaDenosumab | 12 | $36,827 |
| Mirabegron ErMirabegron | 19 | $7,865 |
| Tadalafil | 40 | $7,623 |
| Trimethoprim | 89 | $6,381 |
| Estradiol | 75 | $5,923 |
| Finasteride | 441 | $5,297 |
| ElmironPentosan Polysulfate Sodium | 15 | $4,690 |
| Tamsulosin Hcl | 378 | $4,459 |
| Solifenacin Succinate | 117 | $4,169 |
| Potassium Citrate ErPotassium Citrate | 65 | $4,123 |
| Fosfomycin Tromethamine | 19 | $3,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,232 | $1,027,002326 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $161 | $64,49580 claims |
| AmgenXgeva | $39 | $36,82712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 urology providers in Wisconsin.
Other urology in Berlin
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Kevin FlynnNeenah$56K
- Margaret KnoedlerMadison$31K
- Jeremy ReesePleasant Prairie$27K
- Edwin AbelMadison$22K
- Christopher WalshWauwatosa$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.